Obsidian Therapeutics has enrolled the first patient in the registration-enabling [...]

The first UK patient has been dosed with a personalised [...]

Atsena Therapeutics has received EMA orphan designation for two gene [...]

Lonza is expanding its commercial-scale aseptic drug product capacity in [...]

Enterome Phase 1/2 data show EO2463-induced CD8 T-cell expansion was [...]

EpilepsyGTx has partnered with ClearPoint Neuro to support the targeted [...]

A Phase 1/1b clinical trial has begun in Australia to [...]

ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]

Autolomous and Cellular Origins have integrated their manufacturing platforms to [...]

Autolomous and Cellular Origins have integrated their platforms to create [...]